FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313477851> ?p ?o ?g. }

• W4313477851 abstract "Abstract Background Ceftolozane/tazobactam is a β-lactam/β-lactamase inhibitor combination with activity against a variety of Gram-negative bacteria, including MDR Pseudomonas aeruginosa. This agent is approved for hospital-acquired and ventilator-associated bacterial pneumonia. However, most real-world outcome data come from small observational cohorts. Thus, we sought to evaluate the utilization of ceftolozane/tazobactam at multiple tertiary hospitals in Houston, TX, USA. Methods We conducted a multicentre retrospective study of patients receiving at least 48 h of ceftolozane/tazobactam therapy from January 2016 through to September 2019 at two hospital systems in Houston. Demographic, clinical and microbiological data were collected, including the infecting bacterial isolate, when available. The primary outcome was composite clinical success at hospital discharge. Secondary outcomes included in-hospital mortality and clinical disposition at 14 and 30 days post ceftolozane/tazobactam initiation. Multivariable logistic regression analysis was used to identify predictors of the primary outcome and mortality. Recovered isolates were tested for susceptibility to ceftolozane/tazobactam and underwent WGS. Results A total of 263 patients were enrolled, and composite clinical success was achieved in 185 patients (70.3%). Severity of illness was the most consistent predictor of clinical success. Combination therapy with ceftolozane/tazobactam and another Gram-negative-active agent was associated with reduced odds of clinical success (OR 0.32, 95% CI 0.16–0.63). Resistance to ceftolozane/tazobactam was noted in 15.4% of isolates available for WGS; mutations in ampC and ftsI were common but did not cluster with a particular ST. Conclusions Clinical success rate among this patient cohort treated with ceftolozane/tazobactam was similar compared with previous experiences. Ceftolozane/tazobactam remains an alternative agent for treatment of susceptible isolates of P. aeruginosa." @default.
• W4313477851 created "2023-01-06" @default.
• W4313477851 creator A5009305511 @default.
• W4313477851 creator A5012936100 @default.
• W4313477851 creator A5013242135 @default.
• W4313477851 creator A5015611728 @default.
• W4313477851 creator A5022540272 @default.
• W4313477851 creator A5027587575 @default.
• W4313477851 creator A5032116424 @default.
• W4313477851 creator A5035365970 @default.
• W4313477851 creator A5045554057 @default.
• W4313477851 creator A5056575626 @default.
• W4313477851 creator A5062460881 @default.
• W4313477851 creator A5065333422 @default.
• W4313477851 creator A5071303931 @default.
• W4313477851 creator A5071940344 @default.
• W4313477851 creator A5075229057 @default.
• W4313477851 creator A5080337533 @default.
• W4313477851 creator A5085225502 @default.
• W4313477851 creator A5087235524 @default.
• W4313477851 creator A5089139574 @default.
• W4313477851 creator A5091663701 @default.
• W4313477851 date "2022-12-29" @default.
• W4313477851 modified "2023-10-14" @default.
• W4313477851 title "Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA" @default.
• W4313477851 cites W1645394504 @default.
• W4313477851 cites W2033235589 @default.
• W4313477851 cites W2075287054 @default.
• W4313477851 cites W2137729811 @default.
• W4313477851 cites W2142343447 @default.
• W4313477851 cites W2147189953 @default.
• W4313477851 cites W2150188452 @default.
• W4313477851 cites W2150729119 @default.
• W4313477851 cites W2154015301 @default.
• W4313477851 cites W2203122858 @default.
• W4313477851 cites W2206905236 @default.
• W4313477851 cites W2567139420 @default.
• W4313477851 cites W2591044857 @default.
• W4313477851 cites W2606412122 @default.
• W4313477851 cites W2620266053 @default.
• W4313477851 cites W2742843304 @default.
• W4313477851 cites W2769609314 @default.
• W4313477851 cites W2795056352 @default.
• W4313477851 cites W2804230504 @default.
• W4313477851 cites W2899536177 @default.
• W4313477851 cites W2975667851 @default.
• W4313477851 cites W2975920332 @default.
• W4313477851 cites W3000500166 @default.
• W4313477851 cites W3009858064 @default.
• W4313477851 cites W3014261949 @default.
• W4313477851 doi "https://doi.org/10.1093/jacamr/dlac131" @default.
• W4313477851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36601551" @default.
• W4313477851 hasPublicationYear "2022" @default.
• W4313477851 type Work @default.
• W4313477851 citedByCount "1" @default.
• W4313477851 countsByYear W43134778512023 @default.
• W4313477851 crossrefType "journal-article" @default.
• W4313477851 hasAuthorship W4313477851A5009305511 @default.
• W4313477851 hasAuthorship W4313477851A5012936100 @default.
• W4313477851 hasAuthorship W4313477851A5013242135 @default.
• W4313477851 hasAuthorship W4313477851A5015611728 @default.
• W4313477851 hasAuthorship W4313477851A5022540272 @default.
• W4313477851 hasAuthorship W4313477851A5027587575 @default.
• W4313477851 hasAuthorship W4313477851A5032116424 @default.
• W4313477851 hasAuthorship W4313477851A5035365970 @default.
• W4313477851 hasAuthorship W4313477851A5045554057 @default.
• W4313477851 hasAuthorship W4313477851A5056575626 @default.
• W4313477851 hasAuthorship W4313477851A5062460881 @default.
• W4313477851 hasAuthorship W4313477851A5065333422 @default.
• W4313477851 hasAuthorship W4313477851A5071303931 @default.
• W4313477851 hasAuthorship W4313477851A5071940344 @default.
• W4313477851 hasAuthorship W4313477851A5075229057 @default.
• W4313477851 hasAuthorship W4313477851A5080337533 @default.
• W4313477851 hasAuthorship W4313477851A5085225502 @default.
• W4313477851 hasAuthorship W4313477851A5087235524 @default.
• W4313477851 hasAuthorship W4313477851A5089139574 @default.
• W4313477851 hasAuthorship W4313477851A5091663701 @default.
• W4313477851 hasBestOaLocation W43134778511 @default.
• W4313477851 hasConcept C126322002 @default.
• W4313477851 hasConcept C151956035 @default.
• W4313477851 hasConcept C156957248 @default.
• W4313477851 hasConcept C167135981 @default.
• W4313477851 hasConcept C177713679 @default.
• W4313477851 hasConcept C2776710477 @default.
• W4313477851 hasConcept C2777637488 @default.
• W4313477851 hasConcept C2777858937 @default.
• W4313477851 hasConcept C2777914695 @default.
• W4313477851 hasConcept C2778193466 @default.
• W4313477851 hasConcept C2778266534 @default.
• W4313477851 hasConcept C2779631663 @default.
• W4313477851 hasConcept C501593827 @default.
• W4313477851 hasConcept C523546767 @default.
• W4313477851 hasConcept C54355233 @default.
• W4313477851 hasConcept C71924100 @default.
• W4313477851 hasConcept C86803240 @default.
• W4313477851 hasConcept C89423630 @default.
• W4313477851 hasConcept C94665300 @default.
• W4313477851 hasConceptScore W4313477851C126322002 @default.
• W4313477851 hasConceptScore W4313477851C151956035 @default.
• W4313477851 hasConceptScore W4313477851C156957248 @default.

• next